<DOC>
	<DOCNO>NCT02504736</DOCNO>
	<brief_summary>To evaluate effect colesevelam LDL level A1c high-risk , dysglycemic South Asians ( diabetes , and/or CAD concomitant metabolic syndrome ) whose LDL remain target despite optimal statin use .</brief_summary>
	<brief_title>Colesevelam , Lipids And Sugars , South Asian Canadian Trial</brief_title>
	<detailed_description>This prospective , non-controlled , open label , multicenter trial colesevelam Canadian South Asian adult high cardiovascular risk . 1 . 15-20 clinical site Ontario , Quebec , Manitoba British Columbia select CCRN 's network primary care physician cardiologist identify patient stable type 2 diabetes document stable CAD metabolic syndrome maximally tolerate statin therapy , LDL &gt; 2.0 mmol/L non-HDL &gt; 2.6 mmol/L . 2 . Following informed consent , patient screen baseline HbA1c , fast blood glucose , lipid profile , renal function liver enzymes . 3 . Baseline demographic , CAD diabetes documentation concurrent drug therapy collect . 4 . 250 eligible patient receive physician prescription colesevelam ( Lodalis ) 625 mg tablet ( 3 tablet take twice daily ) 24 week . 5 . Physicians request change lipid diabetes therapy 24 week course trial . 6 . Patients contact 2 12 week ( visit 3 4 ) via phone call ass adherence prescribe therapy , review concurrent medication assess adverse event . 7 . The week 24 visit ( study visit 5 ) include collection fast blood work per screen visit , review concurrent drug therapy final assessment adverse event .</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Colesevelam Hydrochloride</mesh_term>
	<criteria>Individuals South Asian ethnicity ; selfdeclared , least 3 4 grandparent bear South Asian country ( i.e . India , Pakistan , Bangladesh , Sri Lanka , Nepal Bhutan ) Either Diabetes , Coronary artery disease metabolic syndrome Currently receive maximally tolerate dose statin therapy ( least Atorvastatin 20 mg Rosuvastatin 10 mg ) LDL &gt; 2.0 mmol/L nonHDL &gt; 2.6 mmol/L Patient willing provide write consent Age ≥ 18 year Receiving lipidlowering agent , statin ezetimibe Any change make current lipid lowering therapy last 12 week Uncontrolled diabetes ( HbA1c &gt; 0.10 ) TG &gt; 5.0 mmol/L Significant hepatic renal disease ( ALT &gt; 2x ULN eGFR &lt; 30 mL/min/1.73 m² ) Ongoing participation randomize clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>LDL cholesterol</keyword>
	<keyword>A1c</keyword>
	<keyword>High risk South Asians</keyword>
	<keyword>Colesevelam</keyword>
</DOC>